STAT3 and cancer: Moreover, alternative routes such as cytokine and growth factor receptors, oncogenic kinases (e.g., SRC, BCR-ABL), or non-canonical pathways involving mitochondrial STAT3 and unphosphorylated STAT3 can allow cancer cells to bypass upstream inhibition [18].